Ligand Pharmaceuticals Incorporated (FRA:LGDN)
Germany · Delayed Price · Currency is EUR | Market Cap | 4.01B +121.3% |
| Revenue (ttm) | 238.05M +51.2% |
| Net Income | 133.18M |
| EPS | 6.50 |
| Shares Out | n/a |
| PE Ratio | 30.08 |
| Forward PE | 22.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 198.00 |
| Previous Close | 193.00 |
| Day's Range | 196.00 - 198.00 |
| 52-Week Range | 88.50 - 204.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteopor... [Read more]
News
Ligand price target raised to $266 from $263 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Ligand (LGND) to $266 from $263 and keeps a Buy rating on the shares after Travere Therapeutics (TVTX) announced a…
Ligand to Participate in June Investor Conferences
JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c...
Ligand Pharmaceuticals Proxy statement: Proxy filing
Ligand Pharmaceuticals filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
Ligand reports Q1 adjusted EPS $1.63, consensus $1.80
Reports Q1 revenue $51.72M, consensus $58.86M. “The first few months of 2026 have already proven to be highly productive and transformative for Ligand (LGND),” said Todd Davis, CEO of Ligand.
Ligand backs FY26 adjusted EPS view $8.50-$9.50, consensus $9.21
Backs FY26 revenue view $270M-$310M, consensus $288.97M. The company said, “Ligand (LGND) is reaffirming its 2026 full-year financial guidance, which was raised on April 27, 2026 in connection with th...
Ligand Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 56% royalty revenue and 23% adjusted EPS growth year-over-year, driven by portfolio expansion and the strategic shift to royalty aggregation. The XOMA Royalty acquisition is expected to be immediately accretive, further diversifying assets and accelerating long-term growth.
Ligand Pharmaceuticals Earnings release: Q1 2026
Ligand Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Ligand Pharmaceuticals Slides: Q1 2026
Ligand Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Ligand Pharmaceuticals Quarterly report: Q1 2026
Ligand Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Ligand Reports First Quarter 2026 Financial Results
First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution ...
Orchestra BioMed receives $15M payment from Ligand
Orchestra BioMed (OBIO) announced the receipt of a $15M payment from Ligand (LGND) pursuant to the previously disclosed revenue participation right purchase and sale agreement. The payment completes a...
Ligand to Participate in May Investor Conferences
JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c...
Ligand price target raised to $289 from $243 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Ligand (LGND) to $289 from $243 and keeps a Buy rating on the shares. The firm cites the company’s…
Ligand price target raised to $252 from $235 at RBC Capital
RBC Capital raised the firm’s price target on Ligand (LGND) to $252 from $235 and keeps an Outperform rating on the shares. The company’s acquisition of Xoma is a strong…
Ligand Pharmaceuticals Proxy statement: Proxy filing
Ligand Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the propo...
Ligand price target raised to $255 from $230 at Stifel
Stifel raised the firm’s price target on Ligand (LGND) to $255 from $230 and keeps a Buy rating on the shares after the company agreed to acquire Xoma (XOMA) for…
Ligand price target raised to $260 from $250 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Ligand (LGND) to $260 from $250 and keeps a Buy rating on the shares after the company announced plans to…
Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million
Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the companies said on Monday.
Ligand Pharmaceuticals Transcript: M&A announcement
The acquisition of XOMA Royalty will double the portfolio size, add seven commercial royalties, and over 100 development-stage programs, driving immediate and long-term earnings growth. The all-cash deal is expected to be accretive from 2026, with significant synergies and no shareholder dilution.
Ligand Pharmaceuticals Press release: M&A announcement
Ligand Pharmaceuticals issued a press release on April 27, 2026, disclosing material business information to investors.
Ligand Pharmaceuticals Slides: M&A announcement
Ligand Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on April 27, 2026.
Ligand Pharmaceuticals Proxy statement: Proxy filing
Ligand Pharmaceuticals filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Ligand to acquire Xoma for $39.00 per share in cash
Ligand (LGND) and Xoma (XOMA) announced that the companies have entered into a definitive agreement under which Ligand will acquire Xoma Royalty for $39.00 per share of common stock in…
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator
Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary por...